Measurement of infliximab and anti-drug antibody levels in patients with inflammatory bowel disease

• In: D25 What’s new in industry & science? Part 2 on Thursday, 6 September 2018, 10:40 -10:50
• At: Glasgow (Scotland) (2018)
• Type: Presentation
• By: MASUI, Sho (Kyoto University Hospital, Japan)
• Co-author(s): Sho Masui: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan;Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan
  Atsushi Yonezawa: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan;Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan
  Yasuaki Ikemi: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
  Masaya Denda: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
  Yuki Otani: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
  Satoshi Imai: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
  Makoto Hayakari: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
  Noriko Iwamoto: Leading Technology of Bioanalysis and Protein Chemistry, SHIMADZU Corporation, Kyoto, Japan
  Takashi Shimada: Leading Technology of Bioanalysis and Protein Chemistry, SHIMADZU Corporation, Kyoto, Japan
  Minoru Matsuura: Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
  Hiroshi Nakase: Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
  Kazuo Matsubara: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
  
• Abstract:

  Background

  Infliximab (IFX) is a chimeric mouse/human monoclonal antibody. IFX binds to tumor necrosis factor alpha (TNFα), and then suppresses the inflammation caused by certain autoimmune disorders, such as inflammatory bowel disease (IBD). Due to its immunogenicity, anti-drug antibodies (ADAs) are often produced in patients. Formation of

  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login